Adagene vs Roivant Sciences
Adagene and Roivant Sciences are similar in size: $7.7m and $8.3m of revenue in their latest fiscal years. Adagene grew faster (7332.8% against -71.6%). Adagene kept more of each dollar of sales as profit: a net margin of -229.6% against -3629.2%. Roivant Sciences carries less debt relative to equity (0.0% against 17.3%).
| Latest fiscal year | AdageneADAG, 2025 | Roivant SciencesROIV, 2026 |
|---|---|---|
| Revenue | $7.7m | $8.3m |
| Revenue growth | 7332.8% | -71.6% |
| Net income | −$17.6m | −$300m |
| Operating margin | -279.5% | -6235.7% |
| Net margin | -229.6% | -3629.2% |
| Return on equity | -41.0% | -6.5% |
| Free cash flow | −$15.7m | −$759m |
| Cash | $74.5m | $1.42bn |
| Total debt | $6.1m | $0 |
| Debt to equity | 17.3% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 721 |
| Market value | $113m | $26.20bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 117 sales |